- Report
- January 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Drug Pipelines
- April 2024
- 100 Pages
Global
From €2883EUR$3,000USD£2,474GBP
- Report
- August 2023
- 295 Pages
Global
From €9128EUR$9,500USD£7,836GBP
- Report
- August 2022
- 222 Pages
Global
From €3363EUR$3,500USD£2,887GBP
- Report
- February 2023
- 150 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- January 2019
- 50 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- August 2018
- 34 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- August 2018
- 679 Pages
Global
From €21139EUR$22,000USD£18,146GBP
- Report
- October 2018
- 50 Pages
Global
From €8162EUR$8,495USD£7,007GBP
- Report
- August 2018
- 57 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- July 2018
- 65 Pages
Global
From €9608EUR$10,000USD£8,248GBP
Ozanimod is a drug used to treat immune disorders, such as multiple sclerosis (MS) and ulcerative colitis (UC). It is an oral, selective sphingosine 1-phosphate (S1P) receptor modulator that works by modulating the immune system. Ozanimod is believed to reduce the number of relapses in MS patients and reduce the symptoms of UC. It is also being studied for its potential to treat other immune-mediated diseases, such as Crohn's disease and psoriasis.
Ozanimod is currently approved for use in the United States, Canada, and the European Union. It is also being studied in clinical trials for its potential to treat other immune-mediated diseases.
Companies in the Ozanimod market include Celgene Corporation, Receptos, Inc., and Novartis AG. Show Less Read more
